291 related articles for article (PubMed ID: 23323000)
21. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
[TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4.
Rizk NM; Derbala MF
Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):262-8. PubMed ID: 23137758
[TBL] [Abstract][Full Text] [Related]
23. Low IL10 serum levels as key factor for predicting the sustained virological response to IFNα/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype.
Vasconcelos LR; Moura P; do Carmo RF; Pereira LB; Cavalcanti Mdo S; Aroucha DC; Dutra RA; Pereira LM
Hum Immunol; 2014 Aug; 75(8):895-900. PubMed ID: 24994464
[TBL] [Abstract][Full Text] [Related]
24. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
Pineda JA; Caruz A; Rivero A; Neukam K; Salas I; Camacho A; Palomares JC; Mira JA; Martínez A; Roldán C; de la Torre J; Macías J
Clin Infect Dis; 2010 Oct; 51(7):788-95. PubMed ID: 20804372
[TBL] [Abstract][Full Text] [Related]
25. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.
Gupta AC; Trehanpati N; Sukriti S; Hissar S; Midha V; Sood A; Sarin SK
J Med Virol; 2014 Apr; 86(4):707-12. PubMed ID: 24415442
[TBL] [Abstract][Full Text] [Related]
27. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
[TBL] [Abstract][Full Text] [Related]
28. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
Domagalski K; Pawłowska M; Tretyn A; Halota W; Pilarczyk M; Smukalska E; Linkowska K; Grzybowski T
Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):745-54. PubMed ID: 23314745
[TBL] [Abstract][Full Text] [Related]
29. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
30. IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort.
Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Vincze A; Szereday L; Kisfali P; Melegh B
BMC Res Notes; 2014 Jan; 7():12. PubMed ID: 24398031
[TBL] [Abstract][Full Text] [Related]
31. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
[TBL] [Abstract][Full Text] [Related]
32. IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.
Martínez-Gómez LE; Chávez-Tapia NC; Burguete-García AI; Aguilar-Olivos N; Madrid-Marina V; Román-Bahena M; Orbe-Orihuela C; Misael U; Méndez-Sánchez N
Ann Hepatol; 2012; 11(6):876-81. PubMed ID: 23109451
[TBL] [Abstract][Full Text] [Related]
33. Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.
Pineda JA; Caruz A; Di Lello FA; Camacho A; Mesa P; Neukam K; Rivero-juárez A; Macías J; Gómez-Mateos J; Rivero A
AIDS; 2011 Jul; 25(11):1415-20. PubMed ID: 21572301
[TBL] [Abstract][Full Text] [Related]
34. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
[TBL] [Abstract][Full Text] [Related]
35. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.
Del Campo JA; Ampuero J; Rojas L; Conde M; Rojas A; Maraver M; Millán R; García-Valdecasas M; García-Lozano JR; González-Escribano MF; Romero-Gómez M
Aliment Pharmacol Ther; 2013 Jan; 37(1):74-80. PubMed ID: 23121166
[TBL] [Abstract][Full Text] [Related]
36. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.
Valenti L; Aghemo A; Stättermayer AF; Maggioni P; De Nicola S; Motta BM; Rumi MG; Dongiovanni P; Ferenci P; Colombo M; Fargion S
Aliment Pharmacol Ther; 2012 Jun; 35(12):1434-42. PubMed ID: 22530607
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C.
Jeong SH; Jung YK; Yang JW; Park SJ; Kim JW; Kwon OS; Kim YS; Choi DJ; Kim JH
Clin Mol Hepatol; 2012 Dec; 18(4):360-7. PubMed ID: 23323251
[TBL] [Abstract][Full Text] [Related]
38. Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.
Aghemo A; Degasperi E; Rumi MG; Galmozzi E; Valenti L; De Francesco R; De Nicola S; Cheroni C; Grassi E; Colombo M
Biomed Res Int; 2013; 2013():580796. PubMed ID: 23936821
[TBL] [Abstract][Full Text] [Related]
39. Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness.
Hayashi K; Katano Y; Ishizu Y; Kuzuya T; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
J Gastroenterol Hepatol; 2015 Jan; 30(1):178-83. PubMed ID: 24995561
[TBL] [Abstract][Full Text] [Related]
40. IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.
Liu T; Sha K; Yang L; Wang Y; Zhang L; Liu X; Yang F
PLoS One; 2014; 9(3):e91316. PubMed ID: 24642705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
